Fenwick & West represented MRL Ventures Fund, the strategic life sciences investment arm of Merck & Co., Inc. that is focused on innovative therapeutics companies developing transformative medicines, in Kymera Therapeutics’ $65 million Series B financing. The financing was co-led by 6 Dimensions Capital, Bessemer Venture Partners and Pfizer Ventures with participation by MRL Ventures Fund, Sanofi Ventures, Hatteras Venture Partners and Aju IB Investment, in addition to Kymera’s Series A investors.
The financing will support the advancement of its lead asset into clinical development, and to progress its therapeutic pipeline in oncology and immunology. More information regarding MRL Ventures’ participation in Kymera’s financing can be obtained from the company announcement.
The Fenwick transaction team was led by corporate partner Ian Goldstein, of counsel Brian Hicks and associate Feihong Xu.